Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, its extensive biorepository of tumor samples, and its Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, is moving to Pittsburg. The company announced that it has relocated its headquarters to Pittsburg, an area surrounded by world-renowned universities and medical centers, making the city the “epicenter” of POAI’s artificial intelligence and clinical operations. The company recently announced that it had expanded to nearly 20,000 feet of prime commercial space in the Lawrenceville section of Pittsburgh. The company noted that Pittsburgh is a “catalyst for innovation” in the life sciences, noting the McGowen Institute for Regenerative Medicine and the Pittsburgh Tissue Engineering Initiative. “This move reinforces the company’s commitment to growth, solidifying its footprint and expanding the laboratory and center for artificial intelligence in Pittsburgh,” said Predictive Oncology’s CEO and chair Raymond F. Vennare in the press release. “Our company not only employs some of the world’s leading scientists in their respective fields, but has access to a critical mass of talent, many of whom were drawn to the region by Carnegie Mellon University, the University of Pittsburgh and UPMC Medical Center.”

To view the full press release, visit https://ibn.fm/20vFP

About Predictive Oncology Inc.

Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence (“AI”) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. With PEDAL and the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based, drug-discovery solutions, further complemented by its wholly owned CLIA lab and GMP facilities. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork